Top

Published in:

01-01-2017 | Original Article

The possible role of burden of therapy on the risk of myeloma extramedullary spread

Authors: Silvia Mangiacavalli, A. Pompa, V. Ferretti, C. Klersy, F. Cocito, M. Varettoni, C. S. Cartia, M. Cazzola, A. Corso

Published in: Annals of Hematology | Issue 1/2017

Abstract

Extramedullary relapse (EMR) represents a poor prognostic marker in the course of multiple myeloma (MM). We reviewed data from 329 patients, diagnosed between 2000 and 2010, without extramedullary disease at onset to explore possible risk factors for EMR. The median overall survival of our study cohort was 6.4 years. The risk of EMR was 28 % with a median time from diagnosis to first EMR of 2.2 years (0.2–9.1 years). Patients with soft tissue masses located in extra-osseous organs (EMR-S) showed the worst outcome, compared to those with tumor masses arising from adjacent bone (EMR-B) (median OS 1.6 vs 2.4 years, p = 0.006). In addition, patients with EMR-S showed a significant trend for further development of extramedullary masses in a very short time (3.7 vs 5.7 months for EMR-B, p = 0.043). Multivariate analysis failed to identify any clinically presenting features predictive for EMR. The occurrence of EMR was higher in patients with more complex treatment history, defined on the basis of longer treatment duration (≥6 vs <6 months) and on elevated number of treatment lines administered (>2 vs ≤2 lines) (HR = 4.5, p < 0.001 and HR = 9.0, p < 0.001, respectively, when one or both factors are present).In conclusion, increasing burden of treatment might be a possible risk factor for EMR. MM patients with multiple relapses should be comprehensively investigated including, when possible, a whole-body-targeted radiologic technique to accurately detect EMR. Treatment choice should take into account the very poor outcome for patients with soft tissue involvement.

Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354:1021–1030CrossRefPubMed

Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B et al (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370:1209–1218CrossRefPubMed

San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906–917CrossRefPubMed

Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M et al (2010) Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 28:4621–4629CrossRefPubMed

Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME et al (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11:29–37CrossRefPubMed

Kumar S, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516–2520CrossRefPubMedPubMedCentral

Martinez-Lopez J, Bladè J, Mateos MV, Grande C, Alegre A, Garcia-Larana J et al (2011) Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 118:529–534CrossRefPubMed

Bladé J, Fernández de Larrea C, Rosiñol L, Cibeira MT, Jiménez R, Powles R et al (2011) Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol 29:3805–3812CrossRefPubMed

Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M (2010) Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 21:325–330CrossRefPubMed

10.

Weinstock M, Ghobrial I (2013) Extramedullary multiple myeloma. Leuk Lymphoma 54:1135–1141CrossRefPubMed

11.

Wirk B, Wingard JR, Moreb JS (2013) Extramedullary disease in plasma cell myeloma: the iceberg phenomenon. Bone Marrow Transplant 48:10–18CrossRefPubMed

12.

Moreau P, Polliack A (2013) Extramedullary multiple myeloma: extra-osseous relapse is extra “bad news”, but why? Leuk Lymphoma 54:1349–1350CrossRefPubMed

13.

Papanikolaou X, Repousis P, Tzenou T, Maltezas D, Kotsopoulou M, Megalakaki K et al (2013) Incidence, clinical features, laboratory findings and outcome of patients with multiple myeloma presenting with extramedullary relapse. Leuk Lymphoma 54:1459–1464CrossRefPubMed

14.

Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A et al (2012) Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica 97:1761–1767CrossRefPubMedPubMedCentral

15.

Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A et al (2011) Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 25:906–908CrossRefPubMedPubMedCentral

16.

Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L et al (2014) Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica 99:360–417CrossRefPubMedPubMedCentral

17.

Fernandez de Larrea C, Jimenez R, Rosinol L, Gine’ L, Tovar N, Cibeira MT et al (2014) Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma. Bone Marrow Transplant 49(Jimenez R):223–227CrossRefPubMed

18.

Weinstock M, Aljawai Y, Morgan E et al (2015) Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol 169:851–858CrossRefPubMed

19.

Varga C, Wanling X, Laubach J, Ghobrial IM, O’Donnel EK, Weinstock M et al (2015) Development of extramedullary myeloma in the era of novel agent: no evidence of increased risk with lenalidomide-bortezomib combination. Br J Haematol 169:843–850CrossRefPubMed

20.

Blade J, Fernadez de Larrea C, Rosinol L (2015) Extramedullary disease in multiple myeloma in the era of novel agents. Br J Haematol 169:763–765CrossRefPubMed

21.

Katodritou E, Terpos E, Kastritis E, Delimpasis S, Symeonidis AS, Repousis P et al (2015) Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience. Ann Hematol 94:2033–2042CrossRefPubMed

22.

Touzeau C, Moreau P (2016) How I treat extramedullary myeloma. Blood 127(8):971–976CrossRefPubMed

23.

Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N et al (2013) Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood 121:1819–1823CrossRefPubMedPubMedCentral

24.

Zamagni E, Cavo M (2012) The role of imaging techniques in the management of multiple myeloma. Br J Haematol 159:499–513PubMed

25.

Ludwig H, Miguel JS, Dimopoulos MA, Palumbo A, Garcia Sanz R, Powles R et al (2014) International Myeloma Working Group recommendation for global myeloma care. Leukemia 28:981–992CrossRefPubMed

26.

Mesgnich C, Fardanesh R, Tenembaum L, Chari A, Jagannath S, Kostakoglu L (2014) State of the art imaging in multiple myeloma: comparative review of FDG-PET/CT imaging in various clinical settings. Eur J Rad 63:2203–2223CrossRef

27.

Tirumani SH, Sakellis C, Jacene H, Shinagare AB, Munshi NC, Ramaiya NH et al (2016) Role of FDG-PET/CT in extramedullary multiple myeloma: correlation of FDG-PET/CT findings with clinical outcome. Clin Nucl Med 41:e7–e13CrossRefPubMed

28.

Zamagni E, Nanni C, Mancuso K, Tacchetti P, Pezzi A, Pantani L et al (2015) PET/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma. Clin Cancer Res 21(19):4384–4390CrossRefPubMed

29.

Fernández de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH et al (2013) Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 27:780–791CrossRefPubMed

30.

Pérez-Simón JA, Sureda A, Fernández-Aviles F, Sampol A, Cabrera JR, Caballero D et al (2006) Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia 20:542–545CrossRefPubMed

31.

Qu X, Chen L, Qiu H, Lu H, Wu H, Qiu H et al (2015) Extramedullary manifestation in multiple myeloma bears high incidence of poor cytogenetic aberration and novel agents resistance. Biomed Res Int 2015:787809, Epub 2015 Apr 23CrossRefPubMedPubMedCentral

32.

Greaves M, Maley CC (2012) Clonal evolution in cancer. Nature 481:306–313CrossRefPubMedPubMedCentral

33.

Morgan GJ, Walker BA, Davies FE (2012) The genetic architecture of multiple myeloma. Nat Rev Cancer 12:335–348CrossRefPubMed

34.

Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E et al (2012) Clonal competition with alternating dominance in multiple myeloma. Blood 120:1067–1076CrossRefPubMedPubMedCentral

35.

Egan JB, Shi CX, Tembe W, Christoforides A, KJurdoglu A, Sinari S et al (2012) Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 120:1060–1066CrossRefPubMedPubMedCentral

36.

Magrangeas F, Avet-Loiseau H, Gouraud W, Lode’ L, Decaux O, Godmer P et al (2013) Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia 27:473–481CrossRefPubMed

37.

Bolli N, Avet-Loiseau H, Wedge DC, Van Lool P, Alexandrov LB, Martincorena I et al (2014) Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 5:2997CrossRefPubMedPubMedCentral

38.

Brioli A, Melchor L, Cavo M, Morgan GJ (2014) The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. Br J Haematol 165:441–454CrossRefPubMed

39.

Sevcikova S, Paszekova H, Besse L, Sedlarikova L, Kubaczkova V, Almasi M et al (2015) Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 159:88–93

Title: The possible role of burden of therapy on the risk of myeloma extramedullary spread
Authors: Silvia Mangiacavalli
A. Pompa
V. Ferretti
C. Klersy
F. Cocito
M. Varettoni
C. S. Cartia
M. Cazzola
A. Corso
Publication date: 01-01-2017
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 1/2017
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-016-2847-z

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The possible role of burden of therapy on the risk of myeloma extramedullary spread

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey

Primary neurolymphomatosis as clinical onset of chronic lymphocytic leukemia

Markers of endothelial dysfunction and leucocyte activation in Saudi and non-Saudi haplotypes of sickle cell disease

A new frameshift mutation of the β-spectrin gene associated with hereditary spherocytosis

Myocardial and liver iron overload, assessed using T2* magnetic resonance imaging with an excel spreadsheet for post processing in Tunisian thalassemia major patients

Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page